Press releases

7 October, 2020

Abliva doses the first patient in its KL1333 Phase Ia/b clinical study

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in the company’s ongoing KL1333 Phase Ia/b study has been dosed. In this third part of the study ...

16 September, 2020

Abliva’s Mitochondria Day – today at 2 p.m. – 4 p.m. CEST

Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, today on 16 September at 2 p.m. – 4 p.m. CEST. The purpose o ...

9 September, 2020

Regulatory

Abliva intends to start a pivotal KL1333 study second half 2021

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided to accelerate the KL1333 clinical program, with the intention to start a pivotal Phase II/III clini ...

26 August, 2020

Abliva arranges Mitochondria Day on 16 September 2020 – preliminary program

Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the ...

21 August, 2020

Regulatory

Abliva AB Interim Report January – June 2020

NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner

12 August, 2020

Abliva arranges Mitochondria Day on 16 September 2020

31 July, 2020

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI), today announced an increase of the number of shares and votes in the company of 26,666,666 as a result of a performed directed rights issue, resolved by the Board o ...

10 July, 2020

Abliva receives positive FDA feedback on its KL1333 development plan

Abliva AB (Nasdaq Stockholm: ABLI) today announced that it has received positive feedback from the US Food and Drug Administration (“FDA”) on its KL1333 clinical development plan for the treatment of ...

23 June, 2020

Abliva – Virtual Capital Markets Day today at 3.00 p.m.

Abliva AB (Nasdaq Stockholm: ABLI) – today, 23 June 2020, holds a virtual Capital Markets Day. The theme of the day will be the company's new strategic focus on primary mitochondrial disease, the most ...

16 June, 2020

Abliva invites you to a virtual Capital Markets Day on June 23

Abliva AB (Nasdaq Stockholm: ABLI), invites you to a virtual Capital Markets Day on 23 June at 3.00 p.m. - 4.30 p.m. The theme of the day will be the company's new strategic focus on primary mitochond ...

15 June, 2020

Regulatory

Abliva completes the directed issue of MSEK 20 to Hadean Ventures

On April 22, 2020, the Board of Directors of Abliva AB (publ) ("Abliva" or the "Company") resolved, supported by the authorization granted at the Annual General Meeting on April 25, 2019, on a directe ...

1 June, 2020

Abliva arranges virtual Capital Markets Day on 23 June

Abliva AB (Nasdaq Stockholm: ABLI), invites to a virtual capital markets day on 23 June at 3.00 - 4.30 p.m. CEST. The theme of the day will be the company's new strategic focus on primary mitochondria ...